Unity Biotechnology — Technical Presentation (November 2022)
30 slides from Unity Biotechnology's technical presentation, Nov 1, 2022
Slide 1: UBX1325 Phase 2 BEHOLD DME Study 24 Week Data
Arshad M. Khanani MD, MA, FASRS Director of Clinical Research at Sierra Eye Associates Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO UBX1325 Phase 2 BEHOLD DME Study 24 Week Data 01-Nov-2022 Exhibit 99.2
Slide 2: Special Note Regarding Forward-Looking Statements
Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence and the role it plays in diseases of aging, the pote
Slide 3: UBX1325 Led to Statistically Significant Improvement in Visual Acuity in DME
01-Nov-2022 UBX1325 Led to a Statistically Significant and Clinically Relevant Improvement in Visual Acuity in Patients with Diabetic Macular Edema Built on UNITY’s Senescent Cell Biology Platform A single dose of UBX1325 led to a statistically significant and clinically relevant improvement in visi
Slide 4: UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells
01-Nov-2022 UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision DME: Increased senescence burden Retinal vasculature affected Blood retinal barrier (BRB) Breakdown Loss of vision DME treated with Senolytic intended results: Senescent cel
Slide 5: Proposed Mechanism of Action for UBX1325
UBX1325 Vessel remodeling Diabetic blood vessel Repaired blood vessel - UBX1325 selectively triggers cell death of Sn ECs - UBX1325 reduces retinal inflammation and vascular leakage Senescent (Sn) ECs accumulate in diabetic retinas in areas of disease activity Preclinical data predicts progressive d
Slide 6: UBX1325 Clinical Program Overview
01-Nov-2022 UBX1325 Clinical Program Overview Safety & Tolerability Safety & Efficacy 2020 2021 2022 2023 Phase 1 ENVISION Phase 2 nAMD Study BEHOLD Phase 2 DME Study SAD 24-Week Follow-up nAMD 24 Week Follow-up SAD Study - up to 10 µg 4Q ‘21 1H ‘22 2H ‘22 Long-Term Extension DME Proof of Concept St
Slide 7: UBX1325 Phase BEHOLD Study Historic Data on DME Patients treated with Standard of Care
UBX1325 Phase 2 BEHOLD Study Historic Data on DME Patients treated with Standard of Care 01-Nov-2022
Slide 8: Context for 24wk DME Data: Anti-VEGF Effect Plateau
VISTA BLA 125387 Suppl 48, 25 Mar 2015 01-Nov-2022 Context for 24wk DME Data: After Anti-VEGF Effect Has Plateaued, Patients Gain Approximately 1 Letter in Subsequent 6 Months on Aflibercept Treatment
Slide 9: UBX1325 Phase BEHOLD Study 24-Week Data in Patients With DME
UBX1325 Phase 2 BEHOLD Study 24-Week Data in Patients With DME 01-Nov-2022 9
Slide 10: BEHOLD Study Design, Patient Population, and Endpoints
01-Nov-2022 BEHOLD Study Design, Patient Population, and Endpoints Individuals with Diabetic Macular Edema (with moderate diabetic proliferative retinopathy or better), residual retinal fluid (≥300 µm) and visual acuity deficit (73 ETDRS letters or worse) despite having received repeated anti-VEGF t
Slide 11: BEHOLD: 24-Week BCVA Change from Baseline Met Pre-specified Criteria
01-Nov-2022 BEHOLD: 24-Week BCVA Change from Baseline† Met Pre-specified Criteria for Proof of Concept Sham UBX1325 Difference P-Value Week 18 1.7 5.9 4.3 0.0943* Week 24 -1.4 6.2 7.6 0.0084** ** * UBX1325 Led To A Sustained Improvement In BCVA Through 24 Weeks † MMRM Analysis
Slide 12: BEHOLD: 24-Week BCVA Change Including Post-Rescue Data
01-Nov-2022 BEHOLD: 24-Week BCVA Change from Baseline† Including Post-Rescue Data Sham UBX1325 Difference P-Value Week 18 2.6 5.6 3.0 0.1160* Week 24 1.2 6.4 5.2 0.0068** UBX1325 with As-Needed anti-VEGF Rescue Outperformed Sham with As-Needed Rescue Through 24 Weeks†† ** * † MMRM Analysis †† More r
Slide 13: Greater Proportion of UBX1325 Patients Have Larger Visual Acuity Gains
01-Nov-2022 Greater Proportion of Patients in UBX1325 Arm Have Larger Visual Acuity Gains Compared to Sham at 24 Weeks Gains in BCVA without Rescue Gains in BCVA w/ Rescue
Slide 14: BEHOLD: 24-Week CST Change from Baseline
01-Nov-2022 BEHOLD: 24-Week CST Change from Baseline† Met Pre-specified Criteria for Proof of Concept Sham UBX1325 Difference P-Value Week 18 60.3 8.2 -52.1 0.0278* Week 24 34.6 -5.4 -40.0 0.1244** ** * UBX1325 Stabilized the Retina Compared to Sham-Treatment † MMRM Analysis
Slide 15: BEHOLD: 24-Week CST Change Including Post-rescue Data
Adding anti-VEGF rescue data improved CST in sham arm but not in UBX1325 arm†† LS Mean Sham UBX1325 Difference P-Value Week 24 2.7 -4.2 -6.9 0.7522 01-Nov-2022 BEHOLD: 24-Week CST Change from Baseline† Including Post-rescue Data Sham UBX1325 Difference P-Value Week 18 26.0 8.7 -17.3 0.4179 Week 24 2
Slide 16: Summary of Subgroup Analyses at 24 Weeks
In BEHOLD, 4 subgroup factors with 8 total subgroups (2 each) were evaluated based on baseline values for: BCVA (≤60 vs. >60 ETDRS letters) CST (≤400 vs. >400µm) DRSS Score (<47 vs. ≥47) A1c (≤7 vs. >7%) For the response of BCVA, there was a numeric advantage in all 8 subgroups for UBX1325-treated p
Slide 17: Majority of Patients on UBX1325 Were Rescue-free for Months
01-Nov-2022 Majority of Patients on UBX1325 Were Rescue-free for 6 Months Rescue Eligibility Criteria (Either Triggers Rescue): Increase in CST of +75µm from the lowest value (trough) Decrease in BCVA of -10 ETDRS letters from the highest value (peak) p = 0.0664 No rescue: UBX vs Sham
Slide 18: Summary of Treatment Emergent Adverse Events
01-Nov-2022 Summary of Treatment Emergent Adverse Events Sham (%) (N = 33) UBX1325 10 µg (%) (N = 32) Overall (%) (N = 65) Subjects with at least one TEAE 28 (84.8) 24 (75.0) 52 (80.0) Related TEAE 3 (9.1) 6 (18.8) 9 (13.8) Grade ≥3 TEAE 4 (12.1) 3 (9.4) 7 (10.8) Serious TEAE 3 (9.1)* 4 (12.5)* 7 (1
Slide 19: Examples of Imaging Data
Examples of Imaging Data Normal Optical Coherence Tomograph (OCT) 01-Nov-2022
Slide 20: Patient A Weeks Post Single Injection of UBX1325
01-Nov-2022 PATIENT A Weeks Post Single Injection of UBX1325 BL 4 8 12 Weeks Post Single Injection of UBX1325 18 24 CFBL Week 12 Week 18 Week 24 BCVA (ETDRS letters) +19 +9 +16 CST (µm) -99 -101 -107 Tx History: aflibercept x5/6 mo. w/ last 4 weeks prior to randomization 68 ETDRS Letters 423 µm 84 E
Slide 21: Patient B Weeks Post Single Injection of UBX1325
01-Nov-2022 PATIENT B Weeks Post Single Injection of UBX1325 BL 4 8 12 Weeks Post Single Injection of UBX1325 18 24 CFBL Week 12 Week 18 Week 24 BCVA (ETDRS letters) +8 +11 +10 CST (µm) -304 -336 -194 Tx History: bevacizumab x4 doses/6 mo. w/ last 3 wks prior to randomization 35 ETDRS Letters 584 µm
Slide 22: A Single Injection of UBX1325 Provided Evidence of a Senolytic Improving Visual Acuity
01-Nov-2022 A Single Injection of UBX1325 Provided Evidence of a Senolytic Agent Improving Visual Acuity in Patients with Diabetic Macular Edema Was well tolerated with a favorable safety profile and no intraocular inflammation Improved BCVA that was durable for a minimum of 6 months after one dose
Slide 23: Clinical Development Plan
Clinical Development Plan
Slide 24: Key Highlights from Phase BEHOLD DME Study
01-Nov-2022 Key Highlights from Phase 2 BEHOLD DME Study 24-Week data underscore the therapeutic potential of UBX1325 Visual Acuity Improvement Control of Macular Edema Impact on Retinal Structure
Slide 25: UBX1325 Program Overview and Data Readouts 2022-24
2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D LPI LPLV LPLV DME 1325-02 TLR DBL TLR DBL 1325-01 Ph1 SAD 12/18w efficacy analysis AMD 1325-03 LPI 16w efficacy analysis 24w follow-up DME Pivotal Study* 48w follow-up TLR DBL 2
Slide 26: Concluding Remarks
Concluding Remarks 01-Nov-2022
Slide 27: UBX1325 Has a Differentiated Profile With Best-In-Disease Potential
Potential to meaningfully change the treatment paradigm 01-Nov-2022 UBX1325 Has a Differentiated Profile With Best-In-Disease Potential Safety and Efficacy Profile Current standard of care (Aflibercept) aVEGF/Ang2 bispecific (Faricimab) UBX1325 Favorable safety and PK profile Strong efficacy s
Slide 28: Q&A
Q&A 28
Slide 29: Market Snapshot
Market Snapshot $64.5 million cash, cash equivalents and marketable securities as of June 30, 2022. Completed underwritten offering in August raising $41.8 million in net proceeds Focused capital allocation to extend cash runway into 2024, funding UBX1325 Phase 2 proof-of-concept studies and 48-week
Slide 30: Positioning of UBX1325 in Current DME Therapeutic Landscape
Positioning of UBX1325 in Current DME Therapeutic Landscape ** ~50% of patients on anti-VEGF do not achieve 20/40 vision after 2 years of treatment (Shimura M, et al. Br J Ophthalmol 2020;104:1209–1215) Anti-VEGF non- and sub-responders (residual fluid and visual deficits) Switch to anti-VEGF+UBX132
Unity Biotechnology — Technical Presentation (November 2022) on 6ix